BACKGROUND: An autograft of cultured bone marrow-derived mesenchymal stem cells has already been used in clinical practice. In those @entity1 whose bone marrow cannot be used, a cell allograft with the use of immunosuppressant drugs will be an option in the future. However, little is known about the effects of immunosuppressant drugs on mesenchymal stem cells. This study assessed the effects of immunosuppressant drugs on osteogenic differentiation of mesenchymal stem cells and analyzed the manner in which immunosuppressant drugs modulate the osteogenic effect of @entity619 . METHODS: @entity35 bone marrow cells were cultured with or without @entity619 as an osteogenic supplement. In each experimental group, one of three immunosuppressants ( @entity3446 , @entity205 , or @entity1140 ) was added. As a control, cells were cultured without immunosuppressants. Histologically, mineralization was assessed by @entity622 red S staining and phase-contrast microscopy. Biochemically, alkaline phosphatase activity, @entity460 content, and osteocalcin content were assessed. RESULTS: On histological analysis, no mineralized nodules were seen on @entity622 red S staining or phase-contrast microscopy in the groups not treated with @entity619 , except in the group that was treated with @entity1140 . Mineralized nodules were seen in the groups treated with @entity619 , except in the group that was treated with @entity3446 . On biochemical analysis, it was found that, compared to the control group, @entity3446 reduced alkaline phosphatase activity and the @entity460 content of mesenchymal stem cells; @entity1140 increased alkaline phosphatase activity, @entity460 content, and osteocalcin content; and @entity205 had negligible effects. @entity619 increased alkaline phosphatase activity, @entity460 content, and osteocalcin content, but these effects were decreased by @entity3446 . CONCLUSIONS: @entity3446 did not have an osteogenic effect on mesenchymal stem cells, but inhibited the effect of osteogenic differentiation induced by @entity619 . In contrast, @entity1140 had an osteogenic effect on mesenchymal stem cells. Therefore, @entity1140 might be more useful than @entity3446 in allogeneic transplantation of mesenchymal stem cells.

XXXX as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity622 :: ('MESH:C010078', 'Chemical') :: ['alizarin'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['Rapamycin', 'rapamycin'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone', 'dexamethasone'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine A'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['FK506'] @entity35 :: ('10116', 'Species') :: ['Rat']
@entity3446 :: (MESH:D020123,Chemical) :: ['Rapamycin']
